JPS61130226A - 異所性石灰化における疼痛軽減剤 - Google Patents
異所性石灰化における疼痛軽減剤Info
- Publication number
- JPS61130226A JPS61130226A JP25219884A JP25219884A JPS61130226A JP S61130226 A JPS61130226 A JP S61130226A JP 25219884 A JP25219884 A JP 25219884A JP 25219884 A JP25219884 A JP 25219884A JP S61130226 A JPS61130226 A JP S61130226A
- Authority
- JP
- Japan
- Prior art keywords
- pain
- ectopic calcification
- dihydroxycholecalciferol
- substance
- mitigating agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000002193 Pain Diseases 0.000 title claims abstract description 20
- 230000002308 calcification Effects 0.000 title claims abstract description 15
- 230000000116 mitigating effect Effects 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 8
- FCKJYANJHNLEEP-SRLFHJKTSA-N 24,25-dihydroxycholecalciferol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCC(O)C(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C FCKJYANJHNLEEP-SRLFHJKTSA-N 0.000 claims abstract description 5
- FCKJYANJHNLEEP-XRWYNYHCSA-N (24R)-24,25-dihydroxycalciol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CC[C@@H](O)C(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C FCKJYANJHNLEEP-XRWYNYHCSA-N 0.000 claims abstract 2
- 239000004046 24R,25-dihydroxy-cholecalciferol Substances 0.000 claims abstract 2
- 239000004480 active ingredient Substances 0.000 claims description 3
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 15
- 238000000502 dialysis Methods 0.000 abstract description 4
- 230000007774 longterm Effects 0.000 abstract description 2
- 210000004872 soft tissue Anatomy 0.000 abstract description 2
- 238000001802 infusion Methods 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 230000000694 effects Effects 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000002775 capsule Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- -1 triglyceride ester Chemical class 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- WFDKAKYREYOPOC-UHFFFAOYSA-N ethyl 4-hydroxybenzoate titanium Chemical compound [Ti].C(C)OC(=O)C1=CC=C(O)C=C1 WFDKAKYREYOPOC-UHFFFAOYSA-N 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 210000001913 submandibular gland Anatomy 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP25219884A JPS61130226A (ja) | 1984-11-29 | 1984-11-29 | 異所性石灰化における疼痛軽減剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP25219884A JPS61130226A (ja) | 1984-11-29 | 1984-11-29 | 異所性石灰化における疼痛軽減剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS61130226A true JPS61130226A (ja) | 1986-06-18 |
| JPH0372207B2 JPH0372207B2 (enrdf_load_stackoverflow) | 1991-11-18 |
Family
ID=17233864
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP25219884A Granted JPS61130226A (ja) | 1984-11-29 | 1984-11-29 | 異所性石灰化における疼痛軽減剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS61130226A (enrdf_load_stackoverflow) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58135812A (ja) * | 1982-02-08 | 1983-08-12 | Kureha Chem Ind Co Ltd | マグネシウム代謝調節剤 |
-
1984
- 1984-11-29 JP JP25219884A patent/JPS61130226A/ja active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58135812A (ja) * | 1982-02-08 | 1983-08-12 | Kureha Chem Ind Co Ltd | マグネシウム代謝調節剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0372207B2 (enrdf_load_stackoverflow) | 1991-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3699124B2 (ja) | タイプｉｉ糖尿病のピコリン酸クロム高用量治療 | |
| JPH0132208B2 (enrdf_load_stackoverflow) | ||
| WO1995017889A1 (fr) | Composition therapeutique utile pour traiter l'hyperparathyroidie d'un patient en dialyse artificielle | |
| EP1305018A1 (en) | Method and compositions for prevention and/or treatment of diabetes and glucose modulation | |
| JPH05194209A (ja) | 血管内皮細胞機能改善剤 | |
| EP0765661A2 (en) | Use of docosahexaenoic acid for the manufacture of a medicament for the treatment of glumerulonephritis | |
| JPH0453847B2 (enrdf_load_stackoverflow) | ||
| JPS61130226A (ja) | 異所性石灰化における疼痛軽減剤 | |
| US7033612B2 (en) | Composition and method for treating age-related disorders | |
| JP2024526939A (ja) | 酸化的網膜疾患の進行を抑制する方法 | |
| JPH0372206B2 (enrdf_load_stackoverflow) | ||
| JP2876547B2 (ja) | 抗クル病剤 | |
| JPS61130227A (ja) | 腫瘍における疼痛軽減剤 | |
| JP3816545B2 (ja) | 人工透析患者の皮膚そう痒症治療組成物及び副甲状腺機能亢進症治療組成物 | |
| JPS61109721A (ja) | 骨粗しよう症における疼痛軽減剤 | |
| JPS6221330B2 (enrdf_load_stackoverflow) | ||
| JPS6259091B2 (enrdf_load_stackoverflow) | ||
| WO2008141897A1 (en) | Composition useful for the prevention of adverse effect due to the use of ppar-gamma agonists | |
| US4866047A (en) | Method for inhibiting the formation of urinary calculus utilizing 24,25-(OH)2 -D3 | |
| JPS6011422A (ja) | 抗筋ジストロフイ−症剤 | |
| JPS6345643B2 (enrdf_load_stackoverflow) | ||
| JPS61109722A (ja) | 抗糖尿病性骨減少症剤 | |
| JPH0371411B2 (enrdf_load_stackoverflow) | ||
| JPH03291220A (ja) | アスコクロリン誘導体を有効成分とするＣａ代謝異常改善剤 | |
| EP0313703B1 (en) | Use of 24,25-dihydroxycholecalciferole in the treatment of urinary calculus |